In his book, Gareth Sheridan discusses the restrictive €500,000 cap on executive pay in the context of competitive industries like pharmaceuticals and finance. Sheridan, who has experienced the complexities of Wall Street with his company's 2021 Nasdaq listing, criticizes these limits as detrimental. He emphasizes that such restrictions can compromise a company's ability to attract and retain top talent, thereby affecting innovation and growth in critical sectors. The discussion highlights a broader conversation about executive compensation and its implications for business dynamics.
Gareth Sheridan argues that a €500,000 cap on executive pay overlooks the competitive and innovative nature of industries, particularly in finance and pharmaceuticals.
In 'From No to Nasdaq,' Sheridan shares insight into the harsh realities of Wall Street, emphasizing how strict pay limits can hinder talent acquisition and retention.
Collection
[
|
...
]